Your browser is no longer supported. Please, upgrade your browser.
Settings
PCRX Pacira BioSciences, Inc. daily Stock Chart
PCRX [NASD]
Pacira BioSciences, Inc.
Index- P/E242.94 EPS (ttm)0.18 Insider Own0.40% Shs Outstand41.96M Perf Week-8.84%
Market Cap1.83B Forward P/E18.86 EPS next Y2.32 Insider Trans-36.50% Shs Float41.02M Perf Month19.58%
Income7.40M PEG5.26 EPS next Q0.34 Inst Own- Short Float6.75% Perf Quarter7.50%
Sales354.00M P/S5.18 EPS this Y98.90% Inst Trans3.06% Short Ratio4.36 Perf Half Y-8.65%
Book/sh7.94 P/B5.51 EPS next Y47.80% ROA1.10% Target Price54.67 Perf Year26.39%
Cash/sh9.83 P/C4.45 EPS next 5Y46.20% ROE2.40% 52W Range30.00 - 55.00 Perf YTD1.65%
Dividend- P/FCF41.89 EPS past 5Y64.10% ROI2.60% 52W High-20.49% Beta1.36
Dividend %- Quick Ratio7.80 Sales past 5Y31.60% Gross Margin74.20% 52W Low45.77% ATR1.90
Employees518 Current Ratio8.60 Sales Q/Q22.40% Oper. Margin6.70% RSI (14)51.19 Volatility3.39% 4.48%
OptionableYes Debt/Eq0.90 EPS Q/Q74.40% Profit Margin2.10% Rel Volume0.66 Prev Close44.43
ShortableYes LT Debt/Eq0.90 EarningsMay 02 BMO Payout0.00% Avg Volume634.71K Price43.73
Recom2.40 SMA200.12% SMA507.94% SMA2000.67% Volume418,565 Change-1.58%
May-06-19Upgrade Mizuho Underperform → Neutral $29 → $38
May-02-19Upgrade Stifel Sell → Hold $45
Feb-01-19Downgrade Mizuho Neutral → Underperform
Aug-06-18Downgrade BofA/Merrill Buy → Neutral
Apr-09-18Reiterated H.C. Wainwright Buy $45 → $48
Mar-21-18Reiterated Mizuho Neutral $44 → $31
Feb-16-18Downgrade Needham Buy → Hold
Jan-19-18Initiated Seaport Global Securities Buy $50
Jan-04-18Reiterated Canaccord Genuity Buy $42 → $46
Jan-03-18Initiated Leerink Partners Mkt Perform $46
Dec-18-17Initiated JP Morgan Neutral $47
Nov-29-17Downgrade Mizuho Buy → Neutral $53 → $44
Nov-09-17Resumed H.C. Wainwright Buy $52
Oct-26-17Downgrade Janney Neutral → Sell
Oct-19-17Reiterated Needham Buy $55 → $52
Sep-28-17Initiated Goldman Neutral $41
Sep-07-17Initiated Oppenheimer Perform
Aug-22-17Initiated Needham Buy $55
Aug-21-17Upgrade Janney Sell → Neutral
May-05-17Reiterated Mizuho Buy $57 → $54
May-07-19 08:00AM  Pacira BioSciences to Present at Two Healthcare Conferences in May GlobeNewswire
07:30AM  Phase 4 Study Demonstrates Superiority of EXPAREL plus Bupivacaine versus Bupivacaine Alone in Cesarean Section Procedures GlobeNewswire
May-03-19 11:30AM  Pacira Pharmaceuticals, Inc. (PCRX) Q1 2019 Earnings Call Transcript Motley Fool
08:11AM  Edited Transcript of PCRX earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-02-19 09:00PM  Pacira BioSciences Rocks in Q1 With Strong Momentum for Pain Drug Exparel Motley Fool
09:25AM  Pacira (PCRX) Misses Q1 Earnings Estimates Zacks
08:17AM  Pacira: 1Q Earnings Snapshot Associated Press
08:00AM  Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million GlobeNewswire
May-01-19 01:46PM  Pacira Pre-Earnings Calls Hot as Rival Biotech Sinks Schaeffer's Investment Research +16.15%
12:00PM  Why Heron Therapeutics and Pacira BioSciences Are Moving in Opposite Directions Today Motley Fool
11:53AM  Is Pacira Pharmaceuticals Inc (PCRX) A Good Stock To Buy ? Insider Monkey
Apr-26-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Pacira (PCRX) Zacks
Apr-25-19 10:33AM  Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
07:30AM  Pacira to Report First Quarter 2019 Financial Results on Thursday May 2, 2019 GlobeNewswire
Apr-22-19 12:41PM  Read This Before Selling Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Simply Wall St. +5.27%
Apr-09-19 04:01PM  Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System GlobeNewswire
Apr-02-19 07:30AM  Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-30-19 09:30AM  Why Is Pacira (PCRX) Down 7.6% Since Last Earnings Report? Zacks
Mar-25-19 06:00AM  Pacira's New Steps to Pain Treatment MoneyShow
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-15-19 03:16PM  Did Changing Sentiment Drive Pacira Pharmaceuticalss (NASDAQ:PCRX) Share Price Down By 43%? Simply Wall St.
Mar-13-19 07:30AM  New Analysis Shows Enhanced Recovery Pathway Including EXPAREL Infiltration Facilitates Rapid Discharge, High Satisfaction, and Limited Opioid Use in Medicare Patients Undergoing Total Joint Replacement GlobeNewswire
Mar-07-19 12:02AM  Edited Transcript of PCRX earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 02:41PM  The Funded: A look at women in startups and more than $400M in midweek funding American City Business Journals
08:00AM  Factors of Influence in 2019, Key Indicators and Opportunity within Greif, GCP Applied Technologies, salesforce.com, inc, Chubb, Pacira Pharmaceuticals, and FARO Technologies New Research Emphasizes Economic Growth GlobeNewswire
Mar-05-19 05:05PM  [$$] Pacira Pharmaceuticals Strikes $220 Million Deal to Buy Myoscience The Wall Street Journal
08:59AM  Pacira stock down 1.9% after company announces MyoScience acquisition MarketWatch
07:00AM  Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control GlobeNewswire
Mar-04-19 09:54AM  Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-28-19 01:54PM  Pacira Pharmaceuticals Inc (PCRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:00AM  Pacira Reports Record Fourth Quarter and Full Year Revenues GlobeNewswire
Feb-21-19 07:30AM  Pacira to Report 2018 Financial Results on Thursday February 28, 2019 GlobeNewswire
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-12-19 10:40AM  Why Pacira (PCRX) Could Beat Earnings Estimates Again Zacks
09:53AM  Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings Zacks
07:30AM  Pacira Expands EXPAREL Manufacturing Capacity to Meet Growing Demand GlobeNewswire
Feb-07-19 11:48AM  Should You Be Concerned About Pacira Pharmaceuticals, Inc.s (NASDAQ:PCRX) Historical Volatility? Simply Wall St.
Jan-17-19 07:06PM  Pacira's Study on Exparel Label Expansion Meets Endpoints Zacks
Jan-16-19 07:30AM  EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients GlobeNewswire
Jan-04-19 07:25AM  New Research Coverage Highlights LKQ, Pacira Pharmaceuticals, WellCare Health Plans, Masimo, Workday, and Potbelly Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-03-19 05:43PM  Cara (CARA) Up on IDMC's Recommendation to Continue Trial Zacks -9.52%
07:30AM  Pacira Reports Preliminary 2018 Net EXPAREL® Sales of $331 Million GlobeNewswire
Jan-02-19 11:39AM  An Intrinsic Calculation For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shows Its 34.81% Undervalued Simply Wall St.
09:35AM  Pacira Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-18 07:30AM  New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients GlobeNewswire
Dec-10-18 10:23AM  Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com Zacks
Dec-09-18 07:39PM  Pacira Pharmaceuticals Inc (PCRX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-07-18 07:30AM  Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-30-18 09:15AM  Lilly (LLY) Hits Fresh High: Is There Still Room to Run? Zacks
Nov-27-18 07:30AM  New Data Show EXPAREL Plays a Key Role in Achieving Significant Reductions in Opioid Use, Hospital Stay and Total Hospitalization Costs Following Painful Knee Replacement Surgery GlobeNewswire
Nov-23-18 01:11PM  Is Pacira Pharmaceuticals Incs (NASDAQ:PCRX) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-16-18 07:30AM  Pacira Pharmaceuticals CMO Presents at FDA Advisory Committee Meeting Focused on Assessment of Opioid-Sparing Outcomes in Clinical Trials GlobeNewswire
Nov-09-18 05:47PM  Edited Transcript of PCRX earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 08:20AM  Report: Developing Opportunities within Rayonier Advanced Materials, Health Insurance Innovations, Columbus McKinnon, A. O. Smith, Pacira Pharmaceuticals, and Altice Future Expectations, Projections Moving into 2018 GlobeNewswire
07:30AM  Pacira Pharmaceuticals to Present at Healthcare Conferences in November GlobeNewswire
Nov-05-18 10:38AM  Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates Zacks
Nov-02-18 02:12PM  Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPAREL GlobeNewswire
Nov-01-18 08:56AM  Pacira: 3Q Earnings Snapshot Associated Press +6.69%
08:00AM  Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-30-18 07:30AM  Aetna Offers Expanded Coverage for EXPAREL® in Select Ambulatory Surgical Centers GlobeNewswire
Oct-25-18 07:30AM  Pacira to Report Third Quarter 2018 Financial Results on Thursday November 1, 2018 GlobeNewswire
Oct-17-18 08:25AM  Recent Analysis Shows Repligen, SpartanNash, AZUL SA, Pacira Pharmaceuticals, Ichor, and Scorpio Tankers Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-11-18 07:30AM  New Research Reveals Potency and Quantity of Opioids Prescribed for Postsurgical Pain Poses Danger to Patients, their Families and Friends GlobeNewswire
Sep-28-18 08:31AM  Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher Zacks
Sep-27-18 08:41AM  Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher Zacks
08:37AM  Catalyst Pharmaceuticals (CPRX) Catches Eye: Stock Jumps 6.3% Zacks
Sep-26-18 11:14AM  Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status Zacks
Sep-20-18 11:40AM  Molecular Templates Surges 50%, Inks Cancer Deal With Takeda Zacks
08:53AM  Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options Zacks
08:00AM  Today's Research Reports on Trending Tickers: Pacira Pharmaceuticals and OPKO Health ACCESSWIRE
Sep-19-18 10:28AM  Are Pacira Pharmaceuticals Incs (NASDAQ:PCRX) Interest Costs Too High? Simply Wall St. +7.31%
Sep-18-18 11:18AM  United Therapeutics In-Licenses Rights to IPF Candidate Zacks
Sep-14-18 08:28PM  Edited Transcript of PCRX earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
03:55PM  Pacira Shares Look Expensive, Stifel Says In Bearish Initiation Benzinga
Sep-13-18 09:13AM  Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study Zacks
Sep-11-18 08:55AM  Endocyte (ECYT) Soars: Stock Adds 11.4% in Session Zacks
Sep-05-18 04:44PM  Biogen Begins Phase III Study on Ischemic Stroke Candidate Zacks
Aug-27-18 09:27AM  Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe Zacks
07:54AM  Edited Transcript of PCRX earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-23-18 07:35AM  Consolidated Research: 2018 Summary Expectations for SpartanNash, Encana, Hilltop, Pacira Pharmaceuticals, Menlo Therapeutics, and Rayonier Advanced Materials Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-22-18 11:31AM  Pacira (PCRX) Rides High on Robust Exparel Performance Zacks
Aug-13-18 08:50AM  Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert Zacks
Aug-08-18 07:30AM  Pacira Pharmaceuticals to Present at the 2018 Wedbush Pacgrow Healthcare Conference GlobeNewswire
Aug-06-18 11:18AM  Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-02-18 10:10AM  Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates Zacks +5.91%
09:07AM  Pacira: 2Q Earnings Snapshot Associated Press
08:00AM  Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 09:26AM  Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store? Zacks
Jul-30-18 07:10AM  Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks ACCESSWIRE
Jul-26-18 12:31PM  Why Pacira Pharmaceuticals Stock Is on the Rise Today Motley Fool +12.55%
Jul-25-18 07:30AM  Pacira to Report Second Quarter 2018 Financial Results on Thursday August 2, 2018 GlobeNewswire
Jul-16-18 05:25PM  Pacira Focused on Exparel Development Amid Competition Zacks
Jul-11-18 09:37AM  Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2 Zacks
Jul-10-18 07:30AM  Pacira Reports Preliminary Net EXPAREL® Sales of $80.4 Million for Second Quarter of 2018 GlobeNewswire
Jul-02-18 07:25AM  Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks ACCESSWIRE
Jun-27-18 11:31AM  Investors Are Undervaluing Pacira Pharmaceuticals Inc (NASDAQ:PCRX) By 43.7% Simply Wall St. -5.27%
Jun-22-18 06:52AM  Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment MarketWatch
Jun-19-18 07:30AM  Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China GlobeNewswire
Jun-18-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown-Forman, Pacira Pharmaceuticals, Team, and Solaris Oilfield Infrastructure Fundamental Analysis, Key Performance Indications GlobeNewswire
Jun-15-18 07:30AM  Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL® GlobeNewswire
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kronenfeld Mark A.DirectorMar 06Buy38.971,70066,24410,277Mar 08 04:17 PM
STACK DAVID MCEO and ChairmanDec 18Option Exercise3.5512,00042,600133,683Dec 20 04:30 PM
Wicki AndreasDirectorDec 13Sale46.188,720402,692950,362Dec 14 05:47 PM
Wicki AndreasDirectorDec 12Sale47.845,807277,803959,082Dec 14 05:47 PM
PACE GARY WDirectorNov 19Buy46.184,500207,81032,819Nov 21 04:07 PM
Wicki AndreasDirectorNov 19Sale47.0899046,605964,889Nov 21 05:19 PM
Wicki AndreasDirectorNov 16Sale46.8325,6001,198,775965,879Nov 19 07:17 PM
Wicki AndreasDirectorNov 15Sale47.6444,8982,138,811991,479Nov 19 07:17 PM
STACK DAVID MCEO and ChairmanNov 15Sale47.3915,000710,801121,683Nov 19 04:06 PM
Wicki AndreasDirectorNov 12Sale49.835,478272,9801,036,377Nov 14 08:09 PM
Wicki AndreasDirectorNov 09Sale50.2390645,5081,041,855Nov 13 08:35 PM
Wicki AndreasDirectorNov 08Sale51.1357,3392,931,5831,042,761Nov 13 08:35 PM
PACE GARY WDirectorNov 07Buy51.294,000205,16028,319Nov 09 04:30 PM
Riker Lauren BullaroVice President, FinanceNov 02Option Exercise10.341,00010,34011,474Nov 06 04:25 PM
Riker Lauren BullaroVice President, FinanceNov 02Sale54.351,00054,35010,474Nov 06 04:25 PM
STACK DAVID MCEO and ChairmanOct 11Option Exercise2.9045,000130,650136,683Oct 15 04:30 PM
Riker Lauren BullaroVice President, FinanceSep 24Option Exercise10.341,00010,34011,474Sep 26 05:13 PM
Riker Lauren BullaroVice President, FinanceSep 24Sale50.701,00050,70010,474Sep 26 05:13 PM
Kronenfeld Mark A.DirectorAug 28Buy44.611,00044,6118,577Aug 30 04:34 PM
Riker Lauren BullaroVice President, FinanceAug 22Sale44.481,66774,14810,474Aug 24 04:59 PM
STACK DAVID MCEO and ChairmanAug 15Option Exercise10.5814,091149,079124,745Aug 16 05:14 PM
STACK DAVID MCEO and ChairmanAug 15Sale47.3233,0621,564,43291,683Aug 16 05:14 PM
Williams Kristen MarieCAO and General CounselAug 14Sale47.044,773224,52222,374Aug 16 05:12 PM
STACK DAVID MCEO and ChairmanJun 07Sale36.879,791360,98482,040Jun 08 05:03 PM
STACK DAVID MCEO and ChairmanJun 06Sale35.618,615306,78091,831Jun 08 05:03 PM
Williams Kristen MarieCAO and General CounselJun 04Sale33.022,04067,36119,272Jun 06 08:11 PM
Weiland Robert J.Chief Commercial OfficerJun 04Sale33.0237312,3165,088Jun 06 08:11 PM
Scranton RichardChief Scientific OfficerJun 04Sale33.021,36745,13812,226Jun 06 08:09 PM
Reinhart Charles A. IIIChief Financial OfficerJun 04Sale33.0270823,3788,042Jun 06 08:08 PM
Riker Lauren BullaroVice President, FinanceJun 04Sale33.0280126,4499,641Jun 06 08:09 PM
HASTINGS PAUL JDirectorJun 04Sale33.9077126,1372,747Jun 06 08:07 PM